Veracyte’s (NASDAQ: VCYT) Chief Accounting Officer Jonathan Wygant sold 24,000 company shares on May 22, 2026, generating approximately $1.09 million at an average price of $45.40 per share.
The transaction was disclosed in an SEC Form 4 filing dated May 27, 2026, confirming the exercise of 24,000 fully vested options followed by an immediate open-market sale of the resulting shares.
This type of option exercise with immediate disposition is a common mechanism executives use to monetize equity awards without increasing their outright stock exposure.
The sale reduced Wygant’s direct ownership stake by 34.57%, bringing his directly held share count from approximately 69,000 shares down to 45,434 shares post-transaction.
No indirect entities, trusts, or derivative holdings were reported following the transaction, meaning all activity involved only his directly owned shares.
The size of this sale was materially larger than Wygant’s last disclosed open-market transaction, which involved 10,920 shares sold back in November 2025.
Wygant followed up with a subsequent sale of 1,361 shares on June 2, 2026, involving only directly held shares rather than any additional option exercise, bringing his total to 44,073 shares.
The June 2 sale appeared timed to capitalize on Veracyte’s rising stock price, which climbed steadily after the May transaction and reached a 52-week high of $60.91 at the end of June.
Veracyte shares have performed strongly, posting a 74.15% price gain over the one-year period calculated using May 22, 2026 as the reference date.
That share price strength has been fueled by outstanding first-quarter earnings, with the company reporting a 21% year-over-year revenue increase to $139.1 million for the period.
Following that strong quarterly performance, Veracyte raised its full-year guidance to reflect projected year-over-year revenue growth of 13% to 14% for 2026.
The company carries a market capitalization of $3.70 billion, with trailing twelve-month revenue of $541.74 million and net income of $88.01 million.
Veracyte specializes in genomic diagnostic tests for cancer, including its Afirma, Decipher, Prosigna, Percepta, Envisia, and Immunoscore products, targeting thyroid, prostate, breast, lung, and colon cancers.
The company generates revenue primarily through molecular diagnostic test sales and technology licensing, serving healthcare providers, hospitals, and clinical laboratories globally.
With just over half of his prior-year holding remaining after the two sales, Wygant’s future selling capacity is likely constrained unless new equity awards are granted or vest going forward.
